Advanced Oncotherapy – Change of Registered Office & Trading Address

Advanced Oncotherapy announces a change of Registered Office & Trading Address. The group registered office address is now: Level 17, Dashwood House, 69 Old Broad Street, London EC2M 1QS. And its trading and correspondence address is: Third Floor, Clearwater House, 4-7 Manchester Street, London W1U 3AE Advanced Oncotherapy Plc                 […]

Advanced Oncotherapy – Broker Notes

Advanced Oncotherapy Broker Notes Westhouse retains a Buy recommendation with a Target Price of 25p. Advanced Oncotherapy (AVO) – Analyst Robert Sanders – On Schedule. Two CCL modules are announced as ready for high-power testing. This is the first time two CCL modules will be tested together…the finished proton beam cancer treatment machine (LIGHT system) […]

Daily Telegraph – Shares in Advanced Oncotherapy jump amid chatter of Chinese contract win

By Tara Cunningham, Business Reporter, Daily Telegraph: As global equity markets faltered last week, Advanced Oncotherapy bucked the trend amid chatter of a contract win in China. Speculation Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, secured a second contract in China drove the share price higher last week. While global […]

Advanced Oncotherapy – CCL modules ready for high-power testing

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the two Coupled Cavity Linac modules are now ready for high-power testing at the Company’s facility in Geneva. These two modules will be tested at high power by using the Radio Frequency Power Units provided by ScandiNova and Toshiba and it is […]

Advanced Oncotherapy (AVO) – Sinophi agreement with Jilin University

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, confirms that its partner for the Chinese market, Sinophi Healthcare Limited, has recently signed a Framework Agreement with China-Japan Union Hospital of Jilin University in relation to a proton therapy centre. Advanced Oncotherapy confirms that this Framework Agreement does not as yet […]

Advanced Oncotherapy – Holdings in Company

Advanced Oncotherapy says Mr Alberto Colussi and his company Brahma AG have increased shareholdings in AVO from 238,939,600 shares to 273,062,282 shares with voting right (19.35%).

Health Service Journal – Only together can we beat cancer

Collaboration between public and private organisations is vital if the NHS is to win the war on cancer, says Sanjeev Pandya, CEO of Advanced Oncotherapy (AVO). The government’s latest strategy to improve cancer treatment in the UK is welcome, but extra funding alone is not the answer. Greater collaboration is the key to winning the […]